No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PDSB240517C7500
- 0.04
- -0.01-20.00%
15min DelayClose May 9 15:37 ET
0.04High0.04Low
0.04Open0.05Pre Close3 Volume1.04K Open Interest7.50Strike Price12.00Turnover270.37%IV96.87%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.04Time Value100Contract SizeAmericanOptions Type0.0688Delta0.0868Gamma95.75Leverage Ratio-0.0120Theta0.0000Rho6.59Eff Leverage0.0007Vega
Intraday
- 5D
- 1D
News
Express News | PDS Biotech's VERSATILE-002 Phase 2 Clinical Trial Met Primary Study Endpoints
Express News | PDS Biotechnology Corp: Plans to Initiate a Pivotal Clinical Trial in 2024 to Advance Its Lead Program in Advanced Head and Neck Squamous Cell Cancers
Express News | PDS Biotech Versatile-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic Hpv16-Positive Head and Neck Cancer
Express News | HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Express News | Cantor Fitzgerald Reiterates Overweight on PDS Biotechnology
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets
Comments
$PDS Biotechnology(PDSB.US$ PDS Biotech's VERSATILE-002 Phase 2 Clinical Trial Met Primary Study Endpoints
1
$PDS Biotechnology(PDSB.US$
NEWS
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PDS Biotech's VERSATILE-002 Phase 2 clinical trial for first-line recurrent/metastatic HPV16-positive head and neck cancer met primary study endpoints with a 30-month median overall survival, impressive response rates, and a planned Phase 3 trial in 2024. The trial evaluated the combination of Versamune® HPV + KEYT...
NEWS
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PDS Biotech's VERSATILE-002 Phase 2 clinical trial for first-line recurrent/metastatic HPV16-positive head and neck cancer met primary study endpoints with a 30-month median overall survival, impressive response rates, and a planned Phase 3 trial in 2024. The trial evaluated the combination of Versamune® HPV + KEYT...
1
Read more